MLYS_OUT_1 [2025-03-19 11:13:52 -0400] 2464 Bytes | 651 tokens | Cum: 651 tkns (8.14% of 8k)
==========================================================================

Booyah, my friends! It's already 11:13:51 AM on Wednesday March 19, 2025 ET (UTC-0400), and I've got my eyes locked on Mineralys Therapeutics (MLYS), pushing up to 18.18 from 15.43. Are we in for a serious bull run, or is this just hype? I've pulled the data—let's break it down!

Here's the first list of news for Mineralys Therapeutics:

C1 - Mar-18-25 07:58PM - Is Mineralys Therapeutics, Inc. (MLYS) a Pump and Dump Stock Favored by Hedge Funds?
C2 - Mar-18-25 07:58PM 04:01PM - Mineralys Therapeutics Announces Closing of Underwriters' Option to Purchase Additional Shares in Connection with Public Offering of Common Stock
C3 - Mar-17-25 08:00AM - Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology's Annual Scientific Session & Expo
C4 - Mar-11-25 10:20PM - Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock
C5 - Mar-10-25 04:01PM - Mineralys Therapeutics Announces Proposed Public Offering of Common Stock
C6 - Mar-10-25 04:01PM 01:50PM - Mineralys Therapeutics Unveils Positive Data From Two Trials For Hypertension Drug Candidate
C7 - Mar-10-25 04:01PM 12:57PM - Mineralyss stock soars as hypertension pill scores in two pivotal trials
C8 - Mar-10-25 04:01PM 07:00AM - Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension

ONLY 3 RULES for AI:
==============
1) This is a document retrieval system. You are the analyst-investigator.
2) You can request items from any list to get more details about Mineralys Therapeutics (MLYS)
3) AFTER requesting and reading News and SEC filings you'll get tokens to write a summary, set a score and high price target, and finally take an exit quiz.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.

Thank you for your analysis of Mineralys Therapeutics.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!

Please request a document, read, summarize and score. Say something like "C1".

MLYS_OUT_3 [2025-03-19 11:13:56 -0400] 967 Bytes | 294 tokens | Cum: 947 tkns (11.84% of 8k)
==========================================================================

Showing C3 (chunk 1 of 8): C3:
**Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology's Annual Scientific Session & Expo**
Date: Mar-17-25 08:00AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/17/3043633/0/en/Mineralys-Therapeutics-Announces-Data-from-the-Phase-2-Advance-HTN-Trial-of-Lorundrosat-for-the-Treatment-of-Hypertension-Has-Been-Accepted-as-a-Late-Breaking-Presentation-at-the-2.html

March 17, 2025 08:00 ET| Source:Mineralys Therapeutics, Inc.Mineralys Therapeutics, Inc.

RADNOR, Pa., March 17, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apn

-- More? (MOR) or Next section? (NEX)

MLYS_OUT_5 [2025-03-19 11:13:58 -0400] 1021 Bytes | 310 tokens | Cum: 1260 tkns (15.75% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-19T02:08:14Z - Insider Buying: Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Director Buys 1,296,296 Shares of Stock...
A2 - 2025-03-19T02:09:51Z - Insider Buying: Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Major Shareholder Purchases 600,000 Share...
A3 - 2025-03-18T23:58:31Z - Is Mineralys Therapeutics, Inc. (MLYS) a Pump and Dump Stock Favored by Hedge Funds?...
A4 - 2025-03-18T20:17:11Z - Mineralys Therapeutics Announces Closing of Underwriters' Option to Purchase Additional Shares in Co...
A5 - 2025-03-18T08:10:45Z - Samsara Biocapital Gp, Llc Acquires 600,000 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Sto...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

MLYS_OUT_7 [2025-03-19 11:13:59 -0400] 967 Bytes | 288 tokens | Cum: 1550 tkns (19.38% of 8k)
==========================================================================

Showing A1 (chunk 1 of 6): A1:
**Insider Buying: Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Director Buys 1,296,296 Shares of Stock**Date: 2025-03-19Source: {'uri': 'marketbeat.com', 'dataType': 'news', 'title': 'Market Beat'}URL: https://www.marketbeat.com/instant-alerts/insider-buying-mineralys-therapeutics-inc-nasdaqmlys-director-buys-1296296-shares-of-stock-2025-03-17/Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) Director Ra Capital Management, L.P. acquired 1,296,296 shares of the business's stock in a transaction on Thursday, March 13th. The stock was acquired at an average price of $13.50 per share, with a total value of $17,499,996.00. Following the acquisition, the director now owns 4,280,051 shares in the company, valued at $57,780,688.50. The trade was a 43.45 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link.

Miner

-- More? (MOR) or Next section? (NEX)

MLYS_OUT_9 [2025-03-19 11:14:01 -0400] 1241 Bytes | 355 tokens | Cum: 1907 tkns (23.84% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-09-25T12:00:00Z - Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension
B2 - 2024-09-16T20:00:00Z - MLYS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Mineralys Therapeutics, Inc. and Encourages Investors to Contact the Firm!
B3 - 2024-06-14T12:00:00Z - Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of Directors
B4 - 2024-03-13T20:05:00Z - Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024
B5 - 2024-02-08T18:07:51Z - Why Compass Minerals International Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
B6 - 2024-02-08T15:24:19Z - Arm Holdings Posts Upbeat Results, Joins Hershey, CyberArk Software, Wynn Resorts And Other Big Stocks Moving Higher On Thursday

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

MLYS_OUT_11 [2025-03-19 11:14:11 -0400] 702 Bytes | 185 tokens | Cum: 2094 tkns (26.17% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/09/25/2952886/0/en/Mineralys-Therapeutics-Completes-Target-Enrollment-in-Pivotal-Advance-HTN-Trial-of-Lorundrostat-for-the-Treatment-of-Hypertension.htmlMineralys Therapeutics has completed enrollment for its pivotal Advance-HTN trial evaluating the efficacy and safety of lorundrostat for the treatment of uncontrolled or resistant hypertension. The company expects to announce topline data in Q1 2025.

-- More? (MOR) or Next section? (NEX)

MLYS_OUT_13 [2025-03-19 11:14:12 -0400] 861 Bytes | 242 tokens | Cum: 2524 tkns (31.55% of 8k)
==========================================================================

This is our list of SEC filings.
Read it just by asking.
Don't miss breaking filings!

S5 - 2025-03-12 8-K Item 9.01 Fin Stmnts and Exhibits.

(d) Exhibits.

Exhibit No. Description 1.1

Underwriting Agrmt, dated March 11, 2025, by and among Mineralys Therapeutics, Inc. and BofA Securities, Inc., Evercore Group L.L.C. and Goldman Sachs Co. LLC, as representatives of t...

S6 - 2025-03-10 8-K Item 7.01. Regulation FD Disclosure.

On March 10, 2025, Mineralys Therapeutics, Inc. (the Company) issued a press release announcing positive topline data from its pivotal Launch-HTN Phase 3 and pivotal Advance-HTN Phase 2 trials evaluating the efficacy and safety of lorundrost...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing - but what fun is that?
Response limited to 3 chars.

MLYS_OUT_15 [2025-03-19 11:14:27 -0400] 666 Bytes | 191 tokens | Cum: 2717 tkns (33.96% of 8k)
==========================================================================

Showing S5 (chunk 1 of 1): S5:
Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description 1.1

Underwriting Agreement, dated March 11, 2025, by and among Mineralys Therapeutics, Inc. and BofA Securities, Inc., Evercore Group L.L.C. and Goldman Sachs Co. LLC, as representatives of the several underwriters named therein

5.1

Opinion of Latham Watkins LLP

23.1

Consent of Latham Watkins LLP (included in Exhibit 5.1)

99.1

Press Release dated March 10, 2025

99.2

Press Release dated March 11, 2025

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)...

-- More? (MOR) or Next section? (NEX)

MLYS_OUT_17 [2025-03-19 11:14:39 -0400] 4732 Bytes | 1247 tokens | Cum: 4253 tkns (53.16% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+--------------------+----------------------+-------------------------+----------------------+----------------------+
| Prev Close: 15.43 | RSI (14): 77.80 | Perf Quarter: 52.77% | Insider Trans: 8.21% | Sales Q/Q: - | ROE: -82.24% |
+---------------------+--------------------+----------------------+-------------------------+----------------------+----------------------+
| Target Price: 36.71 | ATR (14): 1.44 | Index: RUT | Option/Short: Yes / Yes | Sales past 5Y: 0.00% | ROI: -92.97% |
+---------------------+--------------------+----------------------+-------------------------+----------------------+----------------------+
| Price: 18.18 | SMA20: 55.54% | Market Cap: 1.14B | Short Float: 6.49% | Income: -177.81M | Sales Surprise: - |
+---------------------+--------------------+----------------------+-------------------------+----------------------+----------------------+
| Change: 17.82% | SMA50: 68.86% | Shs Outstand: 49.82M | Short Ratio: 2.67 | Employees: 51 | EPS Surprise: 9.01% |
+---------------------+--------------------+----------------------+-------------------------+----------------------+----------------------+
| Volume: 825,682 | SMA200: 49.94% | Shs Float: 31.01M | Short Interest: 2.01M | Debt/Eq: 0.00 | P/E: - |
+---------------------+--------------------+----------------------+-------------------------+----------------------+----------------------+
| Avg Volume: 754.19K | Perf Week: 38.67% | Inst Own: 43.38% | Beta: -0.28 | Sales Y/Y TTM: - | Earnings: Feb 12 BMO |
+---------------------+--------------------+----------------------+-------------------------+----------------------+----------------------+
| Rel Volume: 4.14 | Perf Month: 89.37% | Insider Own: 50.62% | Sales: 0.00M | Profit Margin: - | |
+---------------------+--------------------+----------------------+-------------------------+----------------------+----------------------+

The next section covers any insider trading.
If this section is blank, it's because there've been no recent filings.

Inside Trans: Mineralys Therapeutics, Inc. (MLYS) by RA CAPITAL MANAGEMENT, L.P. (Unknown Title) on 2025-03-13
- Common Stock: 1296296 shares at $13.5 (I)

Inside Trans: Mineralys Therapeutics, Inc. (MLYS) by AKKARAJU SRINIVAS (Unknown Title) on 2025-03-13
- Common Stock: 600000 shares at $13.5 (I)

Inside Trans: Mineralys Therapeutics, Inc. (MLYS) by Samsara BioCapital GP, LLC (Unknown Title) on 2025-03-13
- Common Stock: 600000 shares at $13.5 (I)

Inside Trans: Mineralys Therapeutics, Inc. (MLYS) by Rodman David Malcom (Chief Medical Officer) on 2025-03-12
- Common Stock: 6349 shares at $1.08 (D)
- Stock Option: 6349 shares at $0 (D)

Inside Trans: Mineralys Therapeutics, Inc. (MLYS) by RA CAPITAL MANAGEMENT, L.P. (Unknown Title) on 2025-02-13
- Stock Option (Right to Buy): 32900 shares at $0 (I)

Inside Trans: Mineralys Therapeutics, Inc. (MLYS) by DiRocco Derek (Unknown Title) on 2025-02-13
- Stock Option: 32900 shares at $0 (D)

Inside Trans: Mineralys Therapeutics, Inc. (MLYS) by Slingsby Brian Taylor (Unknown Title) on 2025-02-13
- Stock Option: 32900 shares at $0 (D)
- Stock Option: 32900 shares at $0 (D) Footnote: Represents stock options transferred pursuant to an option transfer agreement between the Reporting Person and Catalys Pacific Fund, LP.
- Stock Option: 32900 shares at $0 (I) Footnote: Represents stock options transferred pursuant to an option transfer agreement between the Reporting Person and Catalys Pacific Fund, LP.

Inside Trans: Mineralys Therapeutics, Inc. (MLYS) by AKKARAJU SRINIVAS (Unknown Title) on 2025-02-13
- Stock Option: 32900 shares at $0 (D)

Now we've reached the end of the analysis.
You are now allotted tokens to make a final analysis summary.
Please don't use tokens to explain why you didn't have enough information.
Save that for the survey that comes last.

Finish the summary with two scores: MARKET_SCORE[] and PRICE_TARGET[]

If you think there's a 90% likelihood of an upward moves, say: MARKET_SCORE[90]
If you think the high today will be 50% higher, add to the price. Eg., If the price is $5.00, add 50%: PRICE_TARGET[$7.50]
PRICE_TARGET is the highest it is expected to rise today, so it cannot be less than the current price.

After you have completed that, please provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-10 words headline for news story from first summary paragraph]

MLYS_OUT_19 [2025-03-19 11:14:40 -0400] 561 Bytes | 131 tokens | Cum: 4649 tkns (58.11% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More financial metrics
-> X3 <- More SEC filings & insider data
-> X4 <- Broader sector & market news
-> X5 <- General market sentiment & AI confidence levels
-> X6 <- AI's past analysis on similar companies
-> X7 <- AI's past analysis on this exact company
-> X8 <- Something altogether different (explain...)

MLYS_IN_21 [2025-03-19 11:14:41 -0400] 126 Bytes | 29 tokens | Cum: 4685 tkns (58.56% of 8k)
==========================================================================

====================================
[2025-03-19 08:14:41] # Analysis Completed
Elapsed Time: 50.59 seconds